FIELD: medicine.
SUBSTANCE: invention refers to a method for developing Alzheimer disease cell models for testing medical effectiveness of chemical substances to be further used in medicine, more specifically in treating individual's neurodegenerative diseases caused by neurotoxic effects of beta-amyloid aggregates. A molecular cytotoxic agent is a synthetic analogue of human beta-amyloid 1-42 isomerised in asparagic acid residue in position 7 ([isoD]) (amino acid sequence: DAEFRH[isoD]SGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA). The additional advantage of the present invention is applicability of primary cell cultures as Alzheimer disease models.
EFFECT: advantage of these Alzheimer disease cell models as compared to currently used exogenous-induced models, wherein the cytotoxic effects are caused by a non-modified form of beta-amyloid is a higher ability of the isomerised beta-amyloid to induce both cell necrosis and apoptosis.
2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| EXOGENIC-INDUCED ANIMAL MODEL OF ALZHEIMER DISEASE | 2012 |
|
RU2532525C2 |
| PEPTIDE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | 2018 |
|
RU2679059C1 |
| ANIMAL MODEL OF ZINC-DEPENDENT AMYLOIDOGENESIS IN ALZHEIMER'S DISEASE | 2021 |
|
RU2781331C1 |
| METHOD OF PRODUCTION OF INDUCED PLURIPOTENT STEM CELLS OF PATIENTS WITH DOWN SYNDROME | 2012 |
|
RU2492233C1 |
| PREPARATION FOR SELECTIVE APOPTOTIC ELIMINATION OF TUMOUR CELLS | 2014 |
|
RU2567670C2 |
| METHODS AND COMPOSITIONS FOR TREATING AMYLOID DEPOSITS | 2013 |
|
RU2673484C2 |
| HAEE SYNTHETIC TETRAPEPTIDE AND DERIVATIVES THEREOF INTENDED FOR HUMAN NEURON FUNCTION RECOVERY | 2023 |
|
RU2822603C1 |
| SYNTHETIC TETRAPEPTIDE HAEE AND DERIVATIVES THEREOF INTENDED FOR PROTECTION OF HUMAN NEURON FUNCTION | 2023 |
|
RU2822602C1 |
| METHOD OF IDENTIFYING ISOMERISED ASPARTATE IN BETA-AMYLOID | 2009 |
|
RU2431143C2 |
| COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DISTURBANCES | 2005 |
|
RU2387453C2 |
